Koa Health, a digital mental healthcare provider, has entered into a strategic collaboration with Janssen Pharmaceutica NV, part of products giant Johnson & Johnson.
Through the collaboration, Koa Health will work with Janssen scientists to research the delivery of digital cognitive behavioural therapy (dCBT) for treatment resistant major depressive disorder (MDD) patients, in conjunction with pharmacological treatments.
The agreement was facilitated by Johnson & Johnson Innovation, the group’s collaborative arm.
As part of the programme, Koa Health and Janssen will perform a US multi-site feasibility study to assess the use of dCBT in conjunction with a pharmacological treatment in patients with treatment-resistant depression (TRD).
Oliver Harrison, CEO Koa Health says: “Our goal at Koa Health is to provide easy access to a range of digital mental health solutions which meet the mental health needs of every individual and help them to flourish.
“Treatment-resistant depression and major depressive disorder can be debilitating conditions for patients, having a serious impact on the way they think, feel and act. Patients often experience persistent feelings of sadness or despair and have difficulty with everyday life.
“By trialling the use of digital cognitive behavioural therapy, specifically designed for TRD patients, we aim to improve treatment outcomes in this difficult to treat patient population.”
Depression is the condition most frequently associated with suicide and the average cost of healthcare for a patient with TRD is up to 2.8 times higher than for patients with non-TRD or non-MDD.
The collaboration between Janssen and Koa Health aims to provide vital research into an area of mental health for patients that have endured long-term suffering.
Koa Health is a digital mental healthcare provider that offers integrated mental health solutions, covering the waterfront from improving wellbeing to supporting treatment for a range of common mental disorders.
NHS Forth Valley goes live with RCPCH GrowthAPI integrated with Morse Mobile EPR
Mid and South Essex ICS building new shared care record with Orion Health
Red light can reduce blood glucose levels, study finds
Medical device design standards
Why rethinking funding priorities is key to virtual ward success
Thousands with cancer-causing condition offered life-saving NHS bowel cancer test
Neuromelanin imaging: A new path to brain health insights
Lenus puts automation at heart of diagnostic pathways with CDC Heart Failure roll-out
Gallery will highlight therapeutic power of art
Delays in lockdown skin cancer diagnosis linked to deaths and £6bn costs in Europe
- Insight4 weeks ago
8 tips to brand your new medical device
- Diagnostics3 weeks ago
NHS England launches gene testing programme to identify cancer risk early
- AI6 days ago
Aim AI policies at hardware to ensure safety, experts say
- Robotics4 weeks ago
Synthesis robot harnesses AI to speed up chemical discovery